Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A/S Investors

July 14, 2021 GMT

Click here to join the case

​LOS ANGELES, July 14, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Orphazyme A/S (“Orphazyme” or “the Company”) (NASDAQ : ORPH) investors that acquired securities in connection with FTA’s June 2021 initial public offering.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.


It is alleged in this complaint that Orphazyme made misleading and false statements to the market. Orphazyme’s arimoclomol was not an effective treatment for Inclusion Body Myositis (“IBM”). Additionally, Arimoclomol was not an effective treatment for Amyotrophic Lateral Sclerosis (“ALS”). Orphazyme’s new drug application (“NDA”) for arimoclomol for the treatment of Niemann-Pick disease type C (“NPC”) was incomplete and require∂ additional data to support its benefit-risk analysis. It was not likely that The FDA would approve the Orphazyme’s NDA for arimoclomol. Orphazyme’s public statements were false and materially misleading throughout the class period, based on these facts. Investors suffered damages when the market learned the truth about Orphazyme.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar

Attorney Advertising